Evidence‐based (S3) guideline on (anogenital) lichen sclerosus. JEADV. 2015; 29(10):e1–e43

Andrew Lee,Andrew Lee,J. Bradford,Gayle Fischer,Gayle Fischer

DOI: https://doi.org/10.1111/jdv.13721

2017-01-01

Journal of the European Academy of Dermatology and Venereology

Abstract:Editor We read with interest the Evidence-based (S3) guideline on (anogenital) lichen sclerosus (DOI: 10.111/jdv.13136). In light of recently published evidence regarding the longterm management of vulvar lichen sclerosus from our group (JAMA Dermatol. 2015; 151(10): 1061–1067. doi: 10.1001/jamadermatol.2015.0643), we suggest some amendments to the recommendations in this guideline. We agree that topical corticosteroid remains the gold standard treatment for vulvar lichen sclerosus, however we are much more optimistic about long-term outcomes than the guideline. We have demonstrated that prolonged, preventative topical corticosteroid treatment at a level appropriate to maintain disease suppression prevents scarring in the majority of patients and have not encountered the development of genital cancer in any patient managed in this way. In on our own cohort, the risk of 4%–5% for genital SCC in untreated or partially treated vulvar lichen sclerosus is not an overestimation. In this group, 4.7% of patients developed cancer. All were women who, by their own choice, limited their treatment to suppression of symptoms only or declined to use it at all. We have shown that treatment does influence the prognosis of this disease and if used at appropriate potency has minimal side-effects. We propose that if possible, biopsy be performed at initiation of treatment in adults. We believe if a patient is to be told that she requires lifelong medication for a condition that has a malignancy risk, definitive confirmation of the diagnosis is desirable for the information of that patient and the benefit of her future medical attendants. Additionally, conditions such as lichen simplex chronicus, squamous cell malignancies and extra-mammary Paget’s disease may mimic lichen sclerosus and are ruled out by biopsy. We realise that there are situations where a biopsy is not possible for a various reasons including cost constraints and lack of expertise, however our recommendation relates to what we consider ideal practice. The discovery that clobetasol propionate (CP) could suppress lichen sclerosus was a major advance that had a huge impact on short-term treatment. Unfortunately when it came to long-term management, we consider that its use has become a hindrance. Virtually every publication on vulvar lichen sclerosus since 1991 has been about CP and few authors have investigated alternatives. CP is a superpotent corticosteroid. Not only is this potency not necessary to achieve remission in the majority of patients, but it is in fact too potent for safe long-term control. Therefore, as a result of the need to limit the frequency of its use to reduce its atrophogenic potential, it emerges as a poor choice in the long term, and in our experience may produce a combination of inadequate control, with progression of scarring, and in the presence of unacceptable side-effects. Exclusive use of CP is perhaps the reason that long-term management of vulvar lichen sclerosus has appeared to be unsatisfactory as stated in the guideline. Indeed in a previous study using intermittent CP for long-term management, only 23% of patients achieved complete resolutions of signs. However, our study demonstrates that long-term regimens using regular application of moderate to mild products are not only genuinely safe and effective, but are also able to return skin to normal appearance in the majority of cases. This has the potential to have a very large positive impact on patients’ quality of life. There is no single one-size-fits all corticosteroid regimen to manage the many variations in vulvar lichen sclerosus long term, and statements that suggest that we are awaiting evidence-based trials that show the efficacy of one topical corticosteroid over the other may only serve to prevent change. It is immaterial which topical corticosteroid is used. The endpoint of treatment is skin of normal texture and colour and choice of corticosteroid is titrated to achieve that. We have found that CP is only required in the most severe cases. Treatment should be individually adjusted to each patient’s needs, using the degree of hyperkeratosis as a guide to corticosteroid potency. This in turn requires adequate follow-up. Health systems that deny vulvar lichen sclerosus patients this level of care may have to change. The evidence that adequate suppressive treatment prevents cancer should lead health economists to balance the cost of cancer against the cost of regular treatment and follow-up to prevent cancer. We propose the following amendments to this guideline with respect to vulvar lichen sclerosus: • A confirmatory biopsy prior to commencing treatment should ideally be performed in adults. • Suppression of symptoms should not be the endpoint of treatment: suppression of signs is the goal that prevents disease progression. • Any topical corticosteroid regimen that achieves skin of normal colour and texture is appropriate. • Treatment should be titrated to the needs of the individual patient. • Topical corticosteroid use does not increase the likelihood of the development of genital carcinoma. • Early topical corticosteroid treatment will prevent scarring in nearly all patients. Letters to the Editor e57